Literature DB >> 14530861

The FOXC2 -512C>T variant is associated with hypertriglyceridaemia and increased serum C-peptide in Danish Caucasian glucose-tolerant subjects.

K Yanagisawa1, L Hingstrup Larsen, G Andersen, T Drivsholm, A Cederberg, R Westergren, K Borch-Johnsen, O Pedersen, S Enerbäck, T Hansen.   

Abstract

AIMS/HYPOTHESIS: The transcription factor FOXC2 plays a key role in adipocyte differentiation and the FOXC2 gene is a candidate gene for Type 2 diabetes, obesity and dyslipidaemia. We investigated whether the FOXC2 -512C>T promoter variant is associated with Type 2 diabetes or its intermediary phenotypes in glucose tolerant subjects.
METHODS: The variant was genotyped using PCR-RFLP in 705 unrelated Type 2 diabetic patients, 505 unrelated glucose-tolerant control subjects and 219 glucose-tolerant offspring of Type 2 diabetic probands.
RESULTS: The frequency of the T-allele was 58% (95% CI 56-61%) and 59% (56-62%) among the Type 2 diabetic patients and the unrelated glucose-tolerant control subjects, respectively ( p=0.6). Among the glucose-tolerant subjects, the T-allele carriers had higher fasting serum triglyceride ( p=0.03), fasting serum C-peptide concentrations ( p=0.009) and insulinogenic index ( p=0.04). Furthermore, in glucose-tolerant women, the waist-to-hip ratio was significantly higher in carriers of the T-allele. CONCLUSION/
INTERPRETATION: Our data suggest that the FOXC2 -512C>T variant is not associated with Type 2 diabetes. However, among glucose-tolerant subjects the variant is associated with hypertriglyceridaemia and increased fasting serum C-peptide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530861     DOI: 10.1007/s00125-003-1213-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

Review 1.  Transcriptional regulation of adipogenesis.

Authors:  E D Rosen; C J Walkey; P Puigserver; B M Spiegelman
Journal:  Genes Dev       Date:  2000-06-01       Impact factor: 11.361

Review 2.  Understanding adipose tissue development from transgenic animal models.

Authors:  Philippe Valet; Geneviève Tavernier; Isabelle Castan-Laurell; Jean Sébastien Saulnier-Blache; Dominique Langin
Journal:  J Lipid Res       Date:  2002-06       Impact factor: 5.922

3.  FOXC2 mRNA Expression and a 5' untranslated region polymorphism of the gene are associated with insulin resistance.

Authors:  Martin Ridderstråle; Emma Carlsson; Mia Klannemark; Anna Cederberg; Christina Kösters; Hans Tornqvist; Heidi Storgaard; Allan Vaag; Sven Enerbäck; Leif Groop
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

4.  Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q.

Authors:  Päivi Pajukanta; Hooman Allayee; Kelly L Krass; Ali Kuraishy; Aino Soro; Heidi E Lilja; Rebecca Mar; Marja-Riitta Taskinen; Ilpo Nuotio; Markku Laakso; Jerome I Rotter; Tjerk W A de Bruin; Rita M Cantor; Aldons J Lusis; Leena Peltonen
Journal:  Am J Hum Genet       Date:  2003-03-12       Impact factor: 11.025

Review 5.  Five years on the wings of fork head.

Authors:  E Kaufmann; W Knöchel
Journal:  Mech Dev       Date:  1996-06       Impact factor: 1.882

6.  FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance.

Authors:  A Cederberg; L M Grønning; B Ahrén; K Taskén; P Carlsson; S Enerbäck
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

7.  Genetic variability of the SUR1 promoter in relation to beta-cell function and Type II diabetes mellitus.

Authors:  T Hansen; L Ambye; N Grarup; L Hansen; S M Echwald; J Ferrer; O Pedersen
Journal:  Diabetologia       Date:  2001-10       Impact factor: 10.122

8.  Genetic variation in the human winged helix/forkhead transcription factor gene FOXC2 in Pima Indians.

Authors:  Peter Kovacs; Angela Lehn-Stefan; Michael Stumvoll; Clifton Bogardus; Leslie J Baier
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

9.  Systematic search for single nucleotide polymorphisms in the FOXC2 gene: the absence of evidence for the association of three frequent single nucleotide polymorphisms and four common haplotypes with Japanese type 2 diabetes.

Authors:  Haruhiko Osawa; Hiroshi Onuma; Akiko Murakami; Masaaki Ochi; Tatsuya Nishimiya; Kenichi Kato; Ikki Shimizu; Yasuhisa Fujii; Jun Ohashi; Hideichi Makino
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

  9 in total
  5 in total

1.  Lack of association between metabolic traits and the -512 polymorphism in FOXC2 in german people with normal glucose tolerance.

Authors:  A Fritsche; F Machicao; H Staiger; H U Häring; M Stumvoll
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

Review 2.  Candidate genes for type 2 diabetes.

Authors:  Hemang Parikh; Leif Groop
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

3.  In vitro differentiated adipocytes from a Foxc2 reporter knock-in mouse as screening tool.

Authors:  Anna Cederberg; Mats Grände; Magdalena Rhedin; Xiao-Rong Peng; Sven Enerbäck
Journal:  Transgenic Res       Date:  2009-05-28       Impact factor: 2.788

4.  Genetic polymorphisms and weight loss in obesity: a randomised trial of hypo-energetic high- versus low-fat diets.

Authors:  Thorkild I A Sørensen; Philippe Boutin; Moira A Taylor; Lesli H Larsen; Camilla Verdich; Liselotte Petersen; Claus Holst; Søren M Echwald; Christian Dina; Søren Toubro; Martin Petersen; Jan Polak; Karine Clément; J Alfredo Martínez; Dominique Langin; Jean-Michel Oppert; Vladimir Stich; Ian Macdonald; Peter Arner; Wim H M Saris; Oluf Pedersen; Arne Astrup; Philippe Froguel
Journal:  PLoS Clin Trials       Date:  2006-06-30

5.  Dietary obesity-induced Egr-1 in adipocytes facilitates energy storage via suppression of FOXC2.

Authors:  Jifeng Zhang; Yuan Zhang; Tingwan Sun; Fang Guo; Shengping Huang; Menisha Chandalia; Nicola Abate; Daping Fan; Hong-Bo Xin; Y Eugene Chen; Mingui Fu
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.